meglumine

(redirected from Meglumine antimonate)
Also found in: Medical.

meglumine

[′me·glə‚mīn]
(pharmacology)
N-methyl glucamine
References in periodicals archive ?
The pentavalent antimonial meglumine antimonate (GlucantimeA(r), Aventis, France, 85 mg Sb5+/mL) for intramuscular and intralesional administration and sodium stibogluconate (PentostamA(r), 100 mg Sb5+/mL) for intravenous and intramuscular administration have been used for decades for the treatment of CL, and are the gold standard for other new investigational drugs.10
Local infiltration with antimonials (sodium stibogluconate [SSG]100 mg/mL 0.3-3 mL/lesion or meglumine antimonate 0.2-0.8 mL/lesion) was studied in Saudi Arabia in regions where L.
Although liposomal amphotericin B is the most often advised treatment for VL currently, our results with meglumine antimonate (MA; glucantime), which began with a dose of 20 mg/kg/day for 3 days, was increased to 30 mg/kg/day for 3 days and/or then increased to 60 mg/kg per day for 2 weeks, for a total of 20 days) followed by pentamidine isethionate (PI) every other day for a total 15 doses (2.5 mg/kg/day), gave better results, and is much cheaper [4-6], an important factor for the developing countries.
A double-blind randomized clinical trial of a topical herbal extract (ZHE) vs systemic meglumine antimonate for treatment of cutaneous leishmaniasis in Iran.
Since 1940, the pentavalent antimony compounds sodium stibogluconate and meglumine antimonate have been the mainstays of leishmanial therapy [1,5,10,11].